scFv(EGFR)-CD3zeta CAR-T Lentivirus

The scFv(EGFR)-CD3ζ CAR-T lentivirus is a research-grade lentiviral vector system designed to introduce a first-generation anti-EGFR chimeric antigen receptor into T cells for durable expression and reliable function. Utilizing a lentiviral backbone, this system supports stable genomic integration, enabling sustained CAR expression on the cell surface in both dividing and non-dividing lymphocytes, which is crucial for obtaining consistent functional results in long-term cultures and longitudinal studies. The single-chain variable fragment (scFv) targeting EGFR is designed for high specificity to human EGFR, facilitating the identification of tumor cells overexpressing this receptor and providing a defined target-receptor interaction. As a first-generation construct, this CAR contains the CD3ζ signaling domain but lacks additional co-stimulatory modules; this minimalist structure provides a clear and easily interpretable activation signal, which is valuable in basic research, mechanistic dissection of T cell activation thresholds, and direct comparative studies of co-stimulatory modules.

In terms of applications, the scFv(EGFR)-CD3ζ CAR-T lentivirus is well-suited for preclinical research projects requiring precise investigation of antigen-specific T cell responses. It can be used in in vitro experiments co-culturing with EGFR-positive tumor models to assess cytolytic function, activation marker kinetics, and cytokine secretion, providing a foundational baseline for comparison with more complex second- or third-generation CAR designs. Because this construct contains only CD3ζ-mediated signaling, researchers can quantify how variables such as antigen density, scFv affinity, target cell heterogeneity, or inhibitory microenvironmental signals affect activation thresholds and functional potency. This vector is also valuable in high-throughput screening protocols—it can serve as a stable backbone for evaluating the impact of promoter selection, signal peptide variants, hinge and transmembrane region choices, or scFv mutations on specificity and function. In vivo, it can support exploratory xenograft studies where the first-generation signaling helps minimize confounding co-stimulatory effects while mapping the pharmacodynamic relationship between antigen load and CAR-T activity.